Shield Therapeutics 2017 Loss Widens On Clinical Trials, Higher Costs
Shield Therapeutics PLC on Wednesday reported significantly widened loss for 2017, as it progresses on Feraccru product study and commercialisation.
The specialty pha...
Continue Reading →
